These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25784219)

  • 1. A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients.
    Kondo Y; Zhao Y; Petkau J
    Stat Med; 2015 Jun; 34(13):2165-80. PubMed ID: 25784219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
    Healy BC; Ikle D; Macklin EA; Cutter G
    Mult Scler; 2010 Jul; 16(7):840-7. PubMed ID: 20530124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
    Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
    Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal model for magnetic resonance imaging lesion count data in multiple sclerosis patients.
    MacKay Altman R; Petkau AJ; Vrecko D; Smith A
    Stat Med; 2012 Feb; 31(5):449-69. PubMed ID: 21964585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling new enhancing MRI lesion counts in multiple sclerosis.
    Sorman MP; Bruzzi P; Rovaris M; Barkhof F; Comi G; Miller DH; Cutter GR; Filipp M
    Mult Scler; 2001 Oct; 7(5):298-304. PubMed ID: 11724445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does MRI lesion activity regress in secondary progressive multiple sclerosis?
    Zhao Y; Petkau AJ; Traboulsee A; Riddehough A; Li DK
    Mult Scler; 2010 Apr; 16(4):434-42. PubMed ID: 20167592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials.
    Dong J; Zhao Y; Petkau AJ; Li DK; Riddehough A; Traboulsee A
    Mult Scler; 2015 Jan; 21(1):101-4. PubMed ID: 24852923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity.
    Morgan CJ; Aban IB; Katholi CR; Cutter GR
    Mult Scler; 2010 Aug; 16(8):926-34. PubMed ID: 20562161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
    Bekele BN; Shen Y
    Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.
    Velez de Mendizabal N; Hutmacher MM; Troconiz IF; Goñi J; Villoslada P; Bagnato F; Bies RR
    PLoS One; 2013; 8(9):e73361. PubMed ID: 24039924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The distribution of new enhancing lesion counts in multiple sclerosis: further explorations.
    van den Elskamp I; Knol D; Uitdehaag B; Barkhof F
    Mult Scler; 2009 Jan; 15(1):42-9. PubMed ID: 18845655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A menu-driven software package of Bayesian nonparametric (and parametric) mixed models for regression analysis and density estimation.
    Karabatsos G
    Behav Res Methods; 2017 Feb; 49(1):335-362. PubMed ID: 26956682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis.
    Healy BC; Hayden DL; Sampat MP; Bakshi R; Guttmann CR
    J Neurol Sci; 2009 Mar; 278(1-2):54-9. PubMed ID: 19121526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study.
    Schmid VJ; Whitcher B; Padhani AR; Taylor NJ; Yang GZ
    Magn Reson Med; 2009 Jan; 61(1):163-74. PubMed ID: 19097226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.
    van den Elskamp IJ; Lembcke J; Dattola V; Beckmann K; Pohl C; Hong W; Sandbrink R; Wagner K; Knol DL; Uitdehaag B; Barkhof F
    Mult Scler; 2008 Jul; 14(6):764-9. PubMed ID: 18611989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An entropy-based nonparametric test for the validation of surrogate endpoints.
    Miao X; Wang YC; Gangopadhyay A
    Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-based clinical trials in relapsing-remitting MS: new sample size calculations based on a longitudinal model.
    Altman RM; Petkau AJ; Vrecko D; Smith A
    Mult Scler; 2012 Nov; 18(11):1600-8. PubMed ID: 22495948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y; Traboulsee A; Petkau AJ; Li D
    Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.